As a globally connected organisation, we partner with clinical and research groups from around the world to improve outcomes for children and adolescents with cancer both in Australia and New Zealand, and overseas.
The broad aim of ANZSA is to improve outcomes for sarcoma and related tumours in the Australian and New Zealand community by undertaking outstanding international basic, translational, clinical and supportive care research.
COGNO was established in 2007, following identification of a need to develop a central mechanism enabling a coordinated, structured approach to the management of large scale multi-centred neuro-oncology trials. COGNO’s main aim is to conduct investigator-initiated and collaborative group trials addressing important clinical questions in patients with brain tumours.
Zero Childhood Cancer is the most exciting childhood cancer research initiative ever undertaken in Australia. This world-leading program brings together all major Australian clinical and research groups working in childhood cancer to offer Australia’s first ever personalised medicine program for children with high-risk or relapsed cancer. Zero Childhood Cancer is an unprecedented collaboration that stands to revolutionise the way childhood cancer is treated, and represents an integral step towards curing every child.
The Hudson Monash Paediatric Precision Medicine Program, a new research initiative, hopes to significantly improve treatment for childhood cancer patients with the greatest unmet clinical need – those diagnosed with brain cancers and solid tumours.
This US-based clinical trials group is the world’s largest organisation devoted exclusively to childhood and adolescent cancer research. The COG unites more than 9000 experts in childhood cancer at more than 200 leading children’s hospitals, universities and cancer centres across North America, Australia, New Zealand and Europe in the fight against childhood cancer.
The COllaborative Network for NEuro-oncology Clinical Trials (CONNECT) seeks to improve outcomes by conducting nimble, scientifically rational, international trials to demonstrate the safety and feasibility of incorporating novel agents and therapeutic modalities into the most effective current regimens for children with newly-diagnosed high-risk brain tumours.
SIOP Europe now encompasses a range of European Trials Groups targeting specific paediatric tumours, including:
- International BFM (I-BFM) study group: leukaemia and lymphoma.
- EuroEwing Consortium: Ewing’s Tumour
- European Hodgkin’s Consortium/ EuroNET-PHL: Hodgkins Lymphoma
- SIOP Europe Neuroblastoma Group (SIOPEN): Neuroblastoma
- European Paediatric Soft Tissue Sarcoma Study Group (EpSSSG): Soft tissue sarcomas
The largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centres. DKFZ has more than 90 divisions and research groups, and more than 3000 employees, of which more than 1200 are scientists. Together, they’re investigating the mechanisms of cancer, identifying cancer risk factors and trying to find strategies to prevent people from getting cancer. DFKZ is developing novel approaches to make tumour diagnosis more precise and treatment of cancer patients more successful.
Affiliated with the University of Toronto, The Hospital for Sick Children (SickKids) is Canada’s most research-intensive hospital and the largest centre dedicated to improving children’s health in the country. As innovators in child health, SickKids improves the health of children by integrating care, research and teaching. With a staff that includes professionals from all disciplines of health care and research, SickKids provides the best in complex and specialised care by creating scientific and clinical advancements; sharing knowledge and expertise; and championing the development of an accessible, comprehensive and sustainable child health system.
Created in 2003 as a non-profit organisation under French law, ITCC gathers 54 European Paediatric Oncology Departments with expertise in conducting early phase trials in children and adolescents, and 22 European research laboratories. The aim of ITCC is to develop novel therapies for the treatment of paediatric and adolescent cancers in cooperation with regulatory bodies, pharmaceutical enterprises, parents and patients.
The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of 18 children’s hospitals that conduct clinical trials of new therapies for children with brain tumours. PNOC’s goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children.
St. Jude’s clinical trials activity emphasises the innovative and collaborative research between doctors and scientists, who work together to find cures for children. St Jude Children’s Research Hospital are committed to translating discoveries in the laboratory into innovative clinical trials for childhood cancer and other life-threatening diseases.
The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham translates cutting edge science into improved patient care, both rapidly and safely, through the design and conduct of large multi-centre/international randomised trials as well as smaller more data intensive phase I trials of novel therapies.